0013776 2026 RIV GB eng J
Šálek, Cyril^G - Hrabovský, Š. - Folber, F. - Kořístek, Z. - Horáček, J.M. - Froňková, E. - Rezková Řezníčková, L. - Pecherková, Pavla - Soukup, Petr - Dluhošová, B. - Polívková, Václava - Křížková, Jitka - Machová Poláková, Kateřina - Vrzalová, Z. - Trka, J. - Cetkovský, Petr - Doubek, M.
Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia.
Haematologica. Vol. 110, no. 7 (2025), s. 1644-1648. ISSN 0390-6078
Grant: Ministerstvo zdravotnictví NU22-03-00210
Institucionální podpora: RVO:00023736
Klíčová slova: blinatumomab * acute lymphoblastic leukemia * Ph-B-cell precursor
Cite Score: 11.300, rok: 2024; SJR: 2.449, rok: 2024; IF: 7.9, rok: 2024
DOI: 10.3324/haematol.2024.287062

Anotace: Blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, is effective in treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL), though most patients relapse despite achieving measurable residual disease (MRD) negativity. The open-label phase 2 Blina-CELL trial evaluated the effects of one cycle of blinatumomab following 7-day pretreatment with dexamethasone and chemotherapy in adult patients with Ph-negative B-ALL. The study was approved by central and institutional review boards and registered on clinicaltrials.gov.